1. Home
  2. COHN vs IMA Comparison

COHN vs IMA Comparison

Compare COHN & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Company Inc.

COHN

Cohen & Company Inc.

HOLD

Current Price

$15.67

Market Cap

54.3M

Sector

Finance

ML Signal

HOLD

IMA

ImageneBio Inc.

HOLD

Current Price

$5.74

Market Cap

54.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COHN
IMA
Founded
1999
2019
Country
United States
United States
Employees
N/A
15
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3M
54.8M
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
COHN
IMA
Price
$15.67
$5.74
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
30.0K
384.9K
Earning Date
05-01-2026
05-15-2026
Dividend Yield
4.35%
N/A
EPS Growth
5537.50
N/A
EPS
4.35
N/A
Revenue
$275,564,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.32
N/A
Revenue Growth
246.19
N/A
52 Week Low
$7.78
$3.94
52 Week High
$32.60
$17.50

Technical Indicators

Market Signals
Indicator
COHN
IMA
Relative Strength Index (RSI) 35.31 51.06
Support Level $10.33 $5.52
Resistance Level $16.48 $7.17
Average True Range (ATR) 1.94 0.40
MACD -0.65 0.03
Stochastic Oscillator 0.00 35.41

Price Performance

Historical Comparison
COHN
IMA

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: